Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.

Biochem Cell Biol

Department of Biochemistry, University of Saskatchewan, SK, Canada.

Published: April 2011

The Wilson disease protein (ATP7B) is a copper-transporting ATPase that is responsible for regulating copper homeostasis in human tissues. ATP7B is associated with cancer resistance to cisplatin, one of the most widely used anticancer drugs. This minireview discusses the possible mechanisms of tumor resistance to cisplatin mediated by ATP7B. Cisplatin binds to the N-terminal cytosolic domain of ATP7B, which contains multiple copper-binding sites. Active platinum efflux catalyzed by ATP7B is unlikely to significantly contribute to cisplatin resistance in vivo. Transient platinum sequestration in the metal-binding domain followed by transfer to an acceptor protein or a low molecular weight compound is proposed as an alternative mechanism of cisplatin detoxification in the cell.

Download full-text PDF

Source
http://dx.doi.org/10.1139/o10-150DOI Listing

Publication Analysis

Top Keywords

resistance cisplatin
12
tumor resistance
8
cisplatin mediated
8
cisplatin
6
atp7b
6
mechanism tumor
4
resistance
4
mediated copper
4
copper transporter
4
transporter atp7b
4

Similar Publications

[Impacts of curcumin on proliferation, migration and cisplatin resistance of bladder cancer cells by regulating LKB1-AMPK-LC3 signaling pathway].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

January 2025

National Key Laboratory of Bioreactors, School of Biological Engineering, East China University of Science and Technology, Shanghai 200237, China. *Corresponding author, E-mail:

Objective To study the impacts of curcumin on the proliferation, migration and cisplatin (DDP) resistance of bladder cancer cells by regulating the liver kinase B1-AMP activated protein kinase-microtubule-associated protein 1 light chain 3 (LKB1-AMPK-LC3) signaling pathway. Methods Human bladder cancer cell line T24 was cultured in vitro, and its DDP resistant T24/DDP cells were induced by cisplatin (DDP). After treating T24 and T24/DDP cells with different concentrations of curcumin, the optimal concentration of curcumin was screened by MTT assay.

View Article and Find Full Text PDF

Knockdown of miR-182 changes the sensitivity of triple-negative breast cancer cells to cisplatin.

Nucleosides Nucleotides Nucleic Acids

January 2025

Division of Hematology, Department of Internal Medicine, Medical Faculty, Tekirdağ Namık Kemal University, Tekirdağ, Turkey.

Breast cancer is the most common malignancy that affects women. MicroRNAs (miRNAs) play an essential role in cancer therapy and regulate many biological processes such as cisplatin resistance. The study's objective was to determine whether miR-182 dysregulation was the cause of cisplatin resistance in TNBC cell line MDA-MB-231.

View Article and Find Full Text PDF

Background/objectives: Intrahepatic cholangiocarcinoma (iCCA) is a malignant liver tumor with a rising global incidence and poor prognosis, largely due to late-stage diagnosis and limited effective treatment options. Standard chemotherapy regimens, including cisplatin and gemcitabine, often fail because of the development of multidrug resistance (MDR), leaving patients with few alternative therapies. Doxycycline, a tetracycline antibiotic, has demonstrated antitumor effects across various cancers, influencing cancer cell viability, apoptosis, and stemness.

View Article and Find Full Text PDF

SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway.

Commun Biol

January 2025

Institute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, China.

The development of cisplatin resistance often results in a grim prognosis in advanced or recurrent bladder cancer. However, effective treatment strategies for cisplatin resistance have not been well established. Herein, we found that overactivation of SRC is associated with cisplatin-resistance.

View Article and Find Full Text PDF

CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness.

J Biol Chem

January 2025

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address:

Article Synopsis
  • Cervical cancer ranks as the fourth most common cancer among women and is a leading cause of cancer-related deaths due to advanced stages and treatment resistance.
  • Researchers investigated the role of an epigenetic regulator, polycomb repressor complex 1 (PRC1), specifically focusing on the subunit CBX2, which is found to be increased in cervical cancer and linked to poor patient outcomes.
  • The study revealed that CBX2 enhances cancer cell growth, provides resistance to treatments like cisplatin and radiation, and helps maintain cancer stem cell properties, suggesting it could be a key factor for cervical cancer prognosis and a potential target for future therapies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!